Document is current
Any future updates will be listed below
-
Authors
Zeitler, Bryan https://orcid.org/0000-0002-4439-0085
Froelich, Steven
Marlen, Kimberly
Shivak, David A
Yu, Qi
Li, Davis
Pearl, Jocelynn R https://orcid.org/0000-0002-4709-9699
Miller, Jeffrey C
Zhang, Lei
Paschon, David E
Hinkley, Sarah J
Ankoudinova, Irina
Lam, Stephen https://orcid.org/0000-0002-2559-4998
Guschin, Dmitry https://orcid.org/0000-0002-4184-0001
Kopan, Lexi
Cherone, Jennifer M
Nguyen, Hoang-Oanh B
Qiao, Guijuan
Ataei, Yasaman
Mendel, Matthew C
Amora, Rainier
Surosky, Richard
Laganiere, Josee
Vu, B Joseph
Narayanan, Anand
Sedaghat, Yalda
Tillack, Karsten
Thiede, Christina
Gärtner, Annette
Kwak, Seung
Bard, Jonathan
Mrzljak, Ladislav
Park, Larry
Heikkinen, Taneli
Lehtimäki, Kimmo K
Svedberg, Marie M
Häggkvist, Jenny
Tari, Lenke
Tóth, Miklós
Varrone, Andrea
Halldin, Christer
Kudwa, Andrea E
Ramboz, Sylvie
Day, Michelle
Kondapalli, Jyothisri
Surmeier, D James
Urnov, Fyodor D
Gregory, Philip D
Rebar, Edward J
Muñoz-Sanjuán, Ignacio https://orcid.org/0000-0003-0353-3577
Zhang, H Steve
- License Information
-
More Information
Article History
Received: 28 February 2017
Accepted: 3 May 2019
First Online: 1 July 2019
Competing interests
: This work was jointly supported by Sangamo Therapeutics, Inc. and CHDI Foundation, Inc. B.Z., K.M., D.A.S., Q.Y., L.Z., D.E.P., S.J.H., S.L., H.-O.B.N., G.Q., M.C.M., R.A., R.S. and E.J.R. are current employees and shareholders of Sangamo Therapeutics, Inc. S.F., D.L., J.R.P., J.C.M., I.A., D.G., L.K., J.M.C., Y.A., J.L., B.J.V., A.N., F.D.U., P.D.G. and H.S.Z. are former employees and shareholders of Sangamo Therapeutics, Inc. and were employed by Sangamo Therapeutics, Inc. when this work was conducted. S.K., J.B., L.M., L.P. and I.M.-S. are employed by CHDI Management, Inc. as advisors to CHDI Foundation, Inc., and declare no conflict of interest. CHDI Foundation, Inc. is a nonprofit biomedical research organization exclusively dedicated to developing therapeutics that substantially improve the lives of those affected by Huntington’s disease, and conducts research in a number of different ways. For the purposes of this manuscript, all research at Psychogenics, Evotec and Charles River Laboratories was conceptualized, planned and directed by the listed authors and conducted under a fee-for-service agreement.
